Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS

Journal of Lipid Research

Volumn 48, Issue 7, 2007, Pages 1607-1617

  Yan, Weiying ^a   Byrd, Gary D ^b   Ogden, Michael W ^b  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b R J REYNOLDS TOBACCO COMPANY   (United States)

Author keywords

Cigarette smoking; Isoprotanes; Liquid chromatography tandem mass spectrometry; Oxidative stress; Prostaglandins; Quantitation; Validation

Indexed keywords

CREATININE; ISOPROSTANE DERIVATIVE; NICOTINE; PROSTAGLANDIN E2;

ACCURACY; ADULT; CALIBRATION; CIGARETTE SMOKING; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID ANALYSIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; ISOMER; LINEAR REGRESSION ANALYSIS; LIQUID CHROMATOGRAPHY; MALE; METABOLITE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; URINALYSIS; VALIDATION STUDY;

ADULT; CHROMATOGRAPHY, LIQUID; DINOPROST; DRUG STABILITY; FEMALE; HUMANS; ISOPROSTANES; MALE; MIDDLE AGED; SMOKING; TANDEM MASS SPECTROMETRY;

EID: 34548170317     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M700097-JLR200     Document Type: Conference Paper

References (72)

1. 2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA. 87: 9383-9387.
2. Taber, D. F., J. D. Morrow, and L. J. Roberts. 1997. A nomenclature system for the isoprostanes. Prostaglandins. 53: 63-67.
3. Rokach, J., S. P. Khanapure, S. W. Hwang, M. Adiyaman, J. A. Lawson, and G. A. FitzGerald. 1997. Nomenclature of isoprostanes: a proposal. Prostaglandins. 54: 853-873.
4. Basu, S., and J. Helmersson. 2005. Factors regulating isoprostane formation in vivo. Antioxid. Redox Signal. 7: 221-235.
5. 2- isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers. 10 (Suppl.): 10-23.
6. Cracowski, J. L., T. Durand, and G. Bessard. 2002. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol. Sci. 23: 360-366.
7. Morrow, J. D. 2005. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thromb. Vasc. Biol. 25: 279-286.
8. 2α-VI, a new marker of oxidative stress, increases following light damage to the mouse retina. Mol. Vis. 13: 190-195.
9. 2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid. Redox Signal. 7: 269-275.
10. Davi, G., A. Falco, and C. Patrono. 2005. Lipid peroxidation in diabetes mellitus. Antioxid. Redox Signal. 7: 256-268.
11. Cracowski, J. L. 2004. Isoprostanes: an emerging role in vascular physiology and disease? Chem. Phys. Lipids. 128: 75-83.
12. Morrow, J. D. 2006. The isoprostanes - unique products of arachidonate peroxidation: their role as mediators of oxidant stress. Curr. Pharm. Des. 12: 895-902.
13. Janssen, L. J., A. Catalli, and P. Helli. 2005. The pulmonary biology of isoprostaes. Antioxid. Redox Signal. 7: 244-255.
14. Badr, K. F., and T. E. Abi-Antoun. 2005. Isoprostanes and the kidney. Antioxid. Redox Signal. 7: 236-243.
15. Kannel, W. B. 1981. Update on the role of cigarette smoking in coronary artery disease. Am. Heart J. 101: 319-328.
16. Frei, B., T. M. Forte, B. N. Ames, and C. E. Cross. 1991. Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Protective effects of ascorbic acid. Biochem. J. 277: 133-138.
17. 2-isoprostanes) in smokers - smoking as a cause of oxidative damage. N. Engl. J. Med. 332: 1198-1203.
18. 2α, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction gas chromatography mass spectrometry. Basal levels in smokers and nonsmokers. Free Radic. Biol. Med. 20: 619-624.
19. Obata, T., K. Tomaru, T. Nagakura, Y. Izumi, and T. Kawamoto. 2000. Smoking and oxidant stress: assay of isoprostane in human urine by gas chromatography-mass spectrometry. J. Chromatogr. B. 746: 11-15.
20. Montuschi, P., J. V. Collins, G. Ciabattoni, N. Lazzeri, M. Corradi, S. A. Kharitonov, and P. J. Barnes. 2000. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med. 162: 1175-1177.
21. Sinzinger, H., J. Kaliman, and A. Oguogho. 2000. Eicosanoid production and lymphatic responsiveness in human cigarette smokers compared with non-smokers. Lymphology. 33: 24-31.
22. 2-isoprostanes and reduces prostacyclin and nitric oxide in umbilical vessels. Prostaglandins Other Lipid Mediat. 57: 269-279.
23. 2-isoprostanes in plasma of smokers. Cancer Epidemiol. Biomarkers Prevent. 11: 7-13.
24. 2-isoprostanes in plasma of nonsmokers exposed to environmental tobacco smoke. Nutr. Cancer. 45: 176-184.
25. Pilz, H., A. Oguogho, F. Chehne, G. Lupattelli, B. Palumbo, and H. Sinzinger. 2000. Quitting cigarette smoking results in a fast improvement of in vivo oxidation injury (determined via plasma, serum and urinary isoprostane). Thromb. Res. 99: 209-221.
26. Oguogho, A., G. Lupattelli, B. Palumbo, and H. Sinzinger. 2000. Isoprostanes quickly normalize after quitting cigarette smoking in healthy adults. Vasa. 29: 103-105.
27. 2α after restarting smoking. Prostaglandins Leukot. Essent. Fatty Acids. 64: 307-310.
28. Reilly, M., N. Delanty, J. A. Lawson, and G. A. FitzGerald. 1996. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 94: 19-25.
29. Zedler, B. K., R. Kinser, J. Oey, B. Nelson, H. J. Roethig, R. A. Walk, P. Kuhl, K. Rustemeier, G. Schepers, K. Von Holt, et al. 2006. Biomarkers of exposure and potential harm in adult smokers of 3-7 mg tar yield (Federal Trade Commission) cigarettes and in adult non-smokers. Biomarkers. 11: 201-220.
30. 2α- possible methodological, mechanistic and clinical implications. J. Chromatogr. B. 794: 237-255.
31. 2α using liquid chromatography-tandem mass spectrometry: increased excretion in diabetics. Prostaglandins Other Lipid Mediat. 62: 173-181.
32. 2α in human plasma and urine by liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. B. 746: 17-24.
33. Hatsukami, D. K., N. L. Benowitz, S. Rennard, C. Oncken, and S. S. Hecht. 2006. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob. Res. 8: 600-622.
34. 2α in human urine using liquid chromatography-tandem mass spectrometry. Free Radic. Biol. Med. 34: 409-418.
35. 2α-I: an index of lipid peroxidation in humans. Proc. Natl. Acad. Sci. USA. 95: 3449-3454.
36. 2- isoprostanes as markers of in vivo lipid peroxidation - a comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal. Biochem. 272: 209-215.
37. 2α: an index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandins Leukot. Essent. Fatty Acids. 58: 319-325.
38. 2-isoprostane formation in elderly men. Atherosclerosis. 181: 201-207.
39. 2α type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay. J. Chromatogr. B. 754: 333-343.
40. Nourooz-Zadeh, J. 1999. Gas chromatography mass spectrometry assay for measurement of plasma isoprostanes. Methods Enzymol. 300: 13-17.
41. 2α and its endogenous β-oxidation products (2,3-dinor and 2,3-dinor-5,6-dihydro) as biomarkers of total body oxidative stress. Biochem. Biophys. Res. Commun. 330: 731-736.
42. 2-isoprostanes by gas chromatography-mass spectrometry. Biochem. Biophys. Res. Commun. 320: 696-702.
43. 2-isoprostanes. Clin. Chem. 47: 1306-1308.
44. 2α in human urine. J. Chromatogr. B. 744: 99-112.
45. 2α in urine of healthy humans and patients with Zellweger syndrome by gas chromatography tandem mass spectrometry. J. Chromatogr. B. 716: 7-17.
46. 2α by high-performance liquid chromatography and gas chromatography mass spectrometry. J. Chromatogr. B. 694: 271-276.
47. Tsukamoto, H., T. Hishinuma, T. Mikkaichi, H. Nakamura, T. Yamazaki, Y. Tomioka, and M. Mizugaki. 2002. Simultaneous quantification of prostaglandins, isoprostane and thromboxane in cell-cultured medium using gas chromatography mass spectrometry. J. Chromatogr. B. 774: 205-214.
48. 2α) by a stable isotope dilution mass spectrometric assay. Anal. Biochem. 269: 326-331.
49. 2α-VI and quantification of iPF(2alpha)-VI in human urine by gas chromatography mass spectrometry. Anal. Biochem. 262: 45-56.
50. 2- isoprostanes using gas chromatography mass spectrometry. Anal. Biochem. 268: 117-125.
51. 2-isoprostane analysis in plasma and urine with high-performance liquid chromatography and gas chromatography/mass spectroscopy. Anal. Biochem. 280: 73-79.
52. 2α in humans. J. Mass Spectrom. 32: 1362-1370.
53. 2- isoprostanes in human urine. Proc. Natl. Acad. Sci. USA. 96: 13381-13386.
54. 2- isoprostanes. Anal. Biochem. 350: 41-51.
55. 2α measured by liquid chromatography mass spectrometry in smokers, ex-smokers, and nonsmokers. Free Radic. Biol. Med. 35: 1301-1309.
56. 2 isoprostane is already increased at the onset of type 1 diabetes mellitus: effect of glycemic control. Metabolism. 53: 1118-1120.
57. Bohnstedt, K. C., B. Karlberg, L. O. Wahlund, M. E. Jonhagen, H. Basun, and S. Schmidt. 2003. Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. 796: 11-19.
58. 2-isoprostane regioisomers and diastereomers by novel liquid chromatographic/mass spectrometric methods. J. Chromatogr. B. 827: 157-164.
59. 2-iso-prostanes as an index of oxidative stress in vivo. Free Radic. Biol. Med. 28: 505-513.
60. 2-isoprostanes in biological fluids and tissues as measurement of oxidant stress. Methods Enzymol. 300: 3-12.
61. 2-isoprostanes possess no vasomotor effects in the rat thoracic aorta, the human internal mammary artery and the human saphenous vein. Br. J. Pharmacol. 135: 1276-1280.
62. FDA/CDER. 2001. Guidance for Industry on Bioanalytical Methods Validation. FDA/CDER, Rockville, MD.
63. MacLellan, J. A., R. J. Traub, and D. R. Fisher. 1988. Performance Testing of Radiobioassay Laboratories: In Vitro Measurements (Urinalysis). Final Report. National Technical Information Service, Springfield, VA. 8-9.
64. Meger, M., I. Meger-Kossien, A. Schuler-Metz, D. Janket, and G. Scherer. 2002. Simultaneous determination of nicotine and eight nicotine metabolites in urine of smokers using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. 778: 251-261.
65. 2-isoprostane regioisomers formed in vivo in the rat. Free Radic. Biol. Med. 23: 943-954.
66. Miller, J. C., and J. N. Miller. 1988. Statistics for Analytical Chemistry. 2nd edition. Ellis Horwood Limited, Chichester, England. 52-57.
67. Keaney, J. F., M. G. Larson, R. S. Vasan, P. W. F. Wilson, I. Lipinska, D. Corey, J. M. Massaro, P. Sutherland, J. A. Vita, and E. J. Benjamin. 2003. Obesity and systemic oxidative stress - clinical correlates of oxidative stress in the Framingham Study. Arterioscler. Thromb. Vasc. Biol. 23: 434-439.
68. Church, D. F., and W. A. Pryor. 1985. Free-radical chemistry of cigarette-smoke and its toxicological implications. Environ. Health Perspect. 64: 111-126.
69. Byrd, G. D., R. A. Davis, W. S. Caldwell, J. H. Robinson, and J. D. deBethizy. 1998. A further study of FTC yield and nicotine absorption in smokers. Psychopharmacology (Berl.) 139: 291-299.
70. Boswell, C., M. Curvall, R. K. Elswick, and D. Leyden. 2000. Modelling nicotine intake in smokers and snuff users using biological fluid nicotine metabolites. Biomarkers. 5: 341-354.
71. Benowitz, N. L., P. Jacob, I. Fong, and S. Gupta. 1994. Nicotine metabolic profile in man - comparison of cigarette-smoking and transdermal nicotine. J. Pharmacol. Exp. Ther. 268: 296-303.
72. 2α. J. Biol. Chem. 274: 1313-1319.